For many biopharmas, it takes years of hard work to transition from being a clinical-stage drugmaker to a commercial one.
While Johnson & Johnson hopes to soon resolve more than 60,000 talc lawsuits with an $8 billion bankruptcy settlement in the ...
For Big Pharma, recent headlines out of China suggest multinational drugmakers are facing their share of challenges in the ...
New York-based health comms agency Calcium+Company is living up to its name, strengthening the bones of its business with the ...
Few pharmaceutical products have taken the market by storm like Roche’s Vabysmo. | Interim results from a late-stage trial of ...
Australia’s CSL is winding down operations at a cell and gene therapy R&D site in California. Kyowa Kirin inked a commercialization and development deal with Kuro Oncology. Plus more.
Trump leans toward selecting surgeon and COVID mandate critic Martin Makary for top FDA job: reports
While president-elect Donald Trump has already made his leadership picks for the Department of Health and Human Services (HHS ...
On the back of several strong quarters and a year already chock-full of manufacturing accords, Korean CDMO Samsung Biologics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback